Details
Stereochemistry | UNKNOWN |
Molecular Formula | C17H14O4 |
Molecular Weight | 282.2907 |
Optical Activity | ( - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1CCC2=C1C=C(O)C(=C2)C(=O)C3=CC=CC=C3
InChI
InChIKey=XMTKXTUIUKKGIL-UHFFFAOYSA-N
InChI=1S/C17H14O4/c18-15-9-13-11(6-7-12(13)17(20)21)8-14(15)16(19)10-4-2-1-3-5-10/h1-5,8-9,12,18H,6-7H2,(H,20,21)
Oxindanac, a non-steroidal anti-inflammatory drug, and is a weak cyclooxygenase inhibitor possessed antipyretic activity. This drug is used as a veterinary inflammatory drug. In addition, oxindanac was studied in phase III clinical trials for the treatment of rheumatic disorders. However, this study was discontinued.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2687006
Eight male volunteers receiving frusemide 40 mg b.d. were also given either oxindanac 300 mg b.d. or placebo in two consecutive periods separated by a treatment-free period, according to a randomized cross-over study design.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
99910-68-6
Created by
admin on Sat Dec 16 10:14:51 GMT 2023 , Edited by admin on Sat Dec 16 10:14:51 GMT 2023
|
PRIMARY | |||
|
0K7U57MH88
Created by
admin on Sat Dec 16 10:14:51 GMT 2023 , Edited by admin on Sat Dec 16 10:14:51 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD